Therapeutic management of *Helicobacter pylori* remains an unsolved issue, no therapy regimen being able to cure the infection in all treated patients. Indeed, a recent study demonstrated that *H. pylori* eradication was achieved in only 89.6% of the 540 patients, even after following three consecutive standard therapies.\[[@ref1]\] Therapy failure mainly depends on both primary bacterial resistance towards antibiotics and patient compliance. In addition, the high cost of some drugs such as clarithromycin and quinolones, prevents their use in developing countries, where a high prevalence of primary metronidazole resistance is also present. To overcome these limitations, furazolidone-based treatments have been suggested in developing countries by the World Gastroenterology Organisation and Latin-America guidelines.\[[@ref2][@ref3]\] On the other hand, the low rate of primary *H. pylori* resistance toward furazolidone in developed countries may render appealing the use of this drug also in these geographic areas.\[[@ref4][@ref5]\] Furazolidone is a synthetic nitrofuran with a broad spectrum of antimicrobial activities widely used in the treatment of bacterial and protozoal infections in both humans and animals.\[[@ref6]\] However, some concerns recently arose in using furazolidone, such as a molecule harboring a potential carcinogenetic effect.\[[@ref7]--[@ref13]\]

The first review on furazolidone-based therapy was published in 1992,\[[@ref14]\] while the last study based on generic nitrofurans drugs was in 2007.\[[@ref15]\] Because such a drug is still available and used in some Asian and South American countries, we performed a pooled-data analysis to update both efficacy and safety of furazolidone-based treatments for *H. pylori* eradication.

PATIENTS AND METHODS {#sec1-1}
====================

Literature search {#sec2-1}
-----------------

A computer-assisted search was performed on PubMed. We searched for all English language articles published before August 2011, using the exploded medical subject heading terms *Helicobacter pylori* and furazolidone. Boolean operators (NOT, AND, OR) also were used in succession to narrow and widen the search. All studies concerning the use of this antibiotic for either first-line or "rescue" therapies were taken into account. Full articles of all relevant studies were retrieved, and manual searches of reference lists from identified relevant articles were performed to find any additional studies that may have been missed. When more than one publication from the same investigator or group was available, only the most updated version, including the entire sample size, was included in this pooled-data analysis, while data published only in abstract form were not considered.

Data extraction {#sec2-2}
---------------

Two investigators (V.D.F and A.Z.) extracted the data from the studies that met the selection criteria. Data were extracted concerning the following items: (1) number of patients included; (2) age (\<18 years: Young patients, and \>18 years: Adult patients); (3) sex distribution; (4) gastroduodenal pathology (either directly provided or calculated); (5) geographic area involved; (6) the antibiotic association used; (7) furazolidone dose (≤100 mg b.i.d; ≥200 mg b.i.d.); (8) therapy duration (≤7 days; 14 days); (9) side effects incidence; and (10) side effects severity grading as: (a) absent; (b) mild (not interfering with daily activities); (c) moderate (frequently interfering with daily activities); (d) marked (impeding daily activity); and (e) severe (causing treatment interruption).\[[@ref16]\] Bacterial eradication rates were calculated at both intention-to-treat (ITT) and per-protocol (PP) analyses.

Statistical analysis {#sec2-3}
--------------------

Statistical analysis was performed by using the Chi-squared test and Fisher\'s exact test, as appropriate. Eradication rates, side effects rates, and their odds ratios with 95% confidence intervals (CIs) were calculated. A model of multivariate logistic regression analysis was performed using the therapeutic outcome and the occurrence of side effects as the dependent variables. As possible candidates for the multivariate model, duration of treatment (≤1 week vs 2 weeks), drug dosage (≤100 mg b.i.d. or ≥200 mg b.i.d.), and bismuth salts inclusion (furazolidone-based therapies with or without bismuth salts), were considered. Variables were kept in the model only if their association with the eradication term improved the fit of the model. The odds ratio (OR) and 95% CI were also calculated. Differences were considered significant at 5% probability level. Analyses were performed by using Statasoft 7.1 program for Windows XP.

RESULTS {#sec1-2}
=======

First-line therapy: Overall eradication rates {#sec2-4}
---------------------------------------------

A total of 31 studies meeting the inclusion criteria were identified, reporting data of patients enrolled from 1997 to 2011. In detail, there were 13 studies from Iran,\[[@ref17]--[@ref29]\] 7 from China,\[[@ref30]--[@ref36]\] 5 from Brazil,\[[@ref37]--[@ref41]\] 2 from Peru,\[[@ref42][@ref43]\] and 1 each from Russia,\[[@ref44]\] The Netherlands,\[[@ref5]\] USA,\[[@ref4]\] and Colombia.\[[@ref45]\] Two studies enrolled pediatric patients.\[[@ref43][@ref44]\] In the 26 studies reporting cure rate at both ITT and PP analysis, *H. pylori* eradication was achieved in 2331 (75.7%, 95% CI=74.2-77.2) out of 3078 patients at ITT analysis, and in 2331 (80.6%, 95% CI=79.1-82) out of 2892 patients at PP analysis, respectively; and the difference being statistically significant (*P*\<0.001; OR: 1.3, 95% CI: 1.1-1.5). In 5 studies,\[[@ref30][@ref31][@ref42]--[@ref44]\] results were exclusively reported at PP analysis, and the infection was cured in 444 (74.8%, 95% CI: 71.3-78.3) out of 593 patients. Therefore, the overall performance at either ITT and PP analysis were 75.7% (95% CI: 74.2-77.2) and 79.6% (95% CI: 78.2-80.9), respectively; and the difference being statistically significant (*P*\<0.001; OR: 1.2, 95% CI: 1.1-1.4). As shown in [Table 1](#T1){ref-type="table"}, the cure rate substantially varied among different geographic areas, the highest value being reported in the USA (96.3% on 27 patients), whereas the lowest success rate was achieved in the Netherlands (43.4% on 23 patients).

###### 
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First-line therapy: Eradication rates following different therapeutic regimens {#sec2-5}
------------------------------------------------------------------------------

Six different furazolidone-based antibiotic combinations have been used. As shown in [Table 2](#T2){ref-type="table"}, the highest cure rate were achieved following either a proton pump inhibitor-based quadruple therapy (96.3%) or ranitidine bismuth citrate-based triple therapy (91.6%), whereas lower success was achieved following unusual combinations (ie, monotherapy, one-day therapy, and so on).

###### 

*Helicobacter pylori* eradication rates following different first-line furazolidone-based regimens
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According to therapy duration, *H. pylori* was cured in 1439 out of 1904 patients and in 892 out of 1174 patients following a 7- or 14-day furazolidone-based regimen, respectively. The comparison between 7- and 14-day regimens found a similar efficacy at ITT analysis (1439/1904, 75.5% vs 892/1174, 75.9%; *P*=0.8), while a significantly higher eradication rate was achieved with the prolonged regimen at PP analysis (892/1068, 83.5% vs 1439/1824, 82.3%; *P*\<0.05; OR: 1.3, 95% CI: 1.1-1.6).

According to the furazolidone dose, comparable eradication rates were achieved following high- (200 mg b.i.d.) and low-dose (100 mg b.i.d.) regimen at ITT (1166/1522, 76.6% vs 962/1284, 74.9%; *P*=0.3), while significantly different cure rate were found at PP analysis (1166/1373, 84.9% vs 1265/1679, 75.3%; *P*\<0.001; OR: 1.8, 95% CI: 1.5-2.2).

First-line therapy: Eradication rates in different diseases {#sec2-6}
-----------------------------------------------------------

Data on eradication rates in different diseases are available in 10 studies \[[Table 3](#T3){ref-type="table"}\].\[[@ref20][@ref24][@ref26][@ref28][@ref35]--[@ref38][@ref41][@ref45]\] Overall, significantly higher *H. pylori* eradication rates were achieved in peptic ulcer than in non-ulcer dyspeptic patients at both ITT (77.7% vs 65.1%, *P*\<0.001; OR: 1.8, 95% CI: 1.4-2.3) and PP analysis (75% vs 62.8%, *P*\<0.01; OR: 1.7, 95% CI: 1.2-2.5). Higher eradication rates were achieved following bismuth salt-containing as compared with proton pumb inhibitor (PPI)-containing furazolidone-based triple therapies in both peptic ulcer (82.0 vs 76.5%, *P*=0.2 at ITT, and 83.6 vs 65.4%, *P*\<0.01 at PP analysis) and non-ulcer dyspepsia patients (59.5% vs 63.2% *P*=0.5 at ITT, and 65.5% vs 44.2%, *P*\<0.01 at PP analysis).
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*Helicobacter pylori* eradication rates in different diseases
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Side effects {#sec2-7}
------------

The prevalence of side effects was evaluated according to furazolidone dose, therapy duration, and bismuth/PPI association. Side effects were reported by 805 (32.2%) of the 2420 patients, overall reporting 1337 symptoms \[[Table 4](#T4){ref-type="table"}\]. According to the severity, symptoms were graded as severe in 93 (11.5%) of 805 patients, accounting for an overall 3.8% incidence. The rate of both side effects (45.2% vs 23.7%, *P*\<0.001; OR: 2.6, 95% CI: 2.2-3.1) and severe side effects (6.9% vs 1.1%, *P*\<0.001; OR: 6.3, 95% CI: 3.5-11.2) was significantly higher following the 200 mg b.i.d. regimen as compared with the 100 mg b.i.d. schedule. Similarly, the incidence of all side effects (54.4% vs 26.5%, *P*\<0.001; OR: 3.3, 95% CI: 2.7-4) and severe side effects (10.4% vs 1.7%, *P*\<0.001; OR: 6.4, 95% CI: 4.1-10) was higher following the 14- as compared with the 7-day regimen. Finally, as compared with PPI-based therapies, bismuth-based regimens were associated with a higher incidence of all side effects (46.1% vs 25.5%, *P*\<0.001; OR: 2.4, 95% CI: 2-2.9), but with a similar occurrence of severe side effects (4.2% vs. 3.6%, *P*=0.5; OR: 1.1, 95% CI: 0.7-1.7).

###### 

Side effects reported

![](SJG-18-11-g004)

Multivariate analysis {#sec2-8}
---------------------

At multivariate logistic regression, only high-dose furazolidone therapy was significantly associated with a higher therapeutic success (OR: 1.5, 95% CI: 1.3-2.7; *P*\<0.001). Occurrence of side effects was higher following a longer treatment duration (OR: 2.9, 95% CI: 2.2-4.1; *P*\<0.001), high-dose furazolidone (OR: 2.3, 95% CI: 1.7-3.2; *P*\<0.001) and bismuth-containing regimen (OR: 2.1, 95% CI: 1.5-2.8; *P*\<0.001).

"Rescue" therapy: Overall eradication rates {#sec2-9}
-------------------------------------------

There were 4 studies from Brazil,\[[@ref46]--[@ref49]\] 2 from Iran,\[[@ref50][@ref51]\] 3 from China,\[[@ref52]--[@ref54]\] 2 from Russia,\[[@ref55][@ref56]\] and 1 each from Ireland,\[[@ref57]\] Germany,\[[@ref6]\] Mexico,\[[@ref58]\] and Pakistan,\[[@ref59]\] reporting data of furazolidone-based rescue therapies. In detail, 64 patients failed three consecutive therapies, 114 two treatments, and 622 patients the first-line therapy. A PPI, furazolidone-based triple therapy was used in 6 therapeutic arms, while a PPI, bismuth salts, furazolidone-based quadruple therapy was used in 12 arms. In all but 2 studies a 200 mg b.i.d. furazolidone dose was administered. Overall, *H. pylori* infection was cured in 621 (77.6%) of 800 patients at ITT analysis and in 621 (81.7%) of 760 patients at PP analysis \[[Table 5](#T5){ref-type="table"}\].
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*Helicobacter pylori* eradication rates following furazolidone-based "rescue" therapies
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DISCUSSION {#sec1-3}
==========

In 1990s, the use of furazolidone in combination with different antibiotics and bismuth salts was considered a good therapeutic choice to cure *H. pylori* infection.\[[@ref27][@ref60][@ref61]\] Nonetheless, some relevant alarms arose for the use of this drug during last decades. Indeed, it has been advised that such a molecule is mutagenic, genotoxic, and potentially carcinogenetic.\[[@ref7]--[@ref11]\] Furazolidone significantly increases frequency of sister chromatid exchange in human lymphocytes both *in vitro* and *in vivo*.\[[@ref9]\] In addition, a dose-related increased incidence of both breast and bronchial adenocarcinomas, as well as of lymphosarcomas, has been observed in animal models.\[[@ref9][@ref10]\] The IARC classified furazolidone as a type 3 carcinogen for humans in 1997,\[[@ref62]\] and both the European Agency for the Evaluation of Medical Products in 1999 and the US Food and Drug Administration agency in 2002 banned its use in animals, in order to avoid the presence of residues in meat-derived foods.\[[@ref11][@ref63][@ref64]\] Furazolidone is not approved by the European Medicines Agency (EMA) either as a human medicine or for animal use,\[[@ref65]\] it has been withdrawn in Yemen,\[[@ref66]\] and it is not currently commercialized in the USA. Recent findings showing that furazolidone exerts a dose-related cytotoxicty in human HepG2 cells by the induction of intracellular reactive oxygen species (ROS) and a DNA oxidative damage would further support these restrictions.\[[@ref10]\] Despite these restrictions, furazolidone use has been proposed in recent guidelines for *H. pylori* management in developing countries, due to its efficacy, low rate of primary bacterial resistance, and lack of alterative, low-cost therapies.\[[@ref2][@ref3]\] In 2007, a meta-analysis evaluated the efficacy of furazolidone-based regimens.\[[@ref15]\] However, further 16 studies have been published in the following years, justifying an update of data. The present systematic review found that first-line furazolidone-based regimens achieve \<80% eradication rate at ITT. Therefore, in agreement with the "report card" proposed by Graham and Fischbach,\[[@ref67]\] these therapies should be considered as not recommendable (grade F) in clinical practice. Moreover, the low eradication rate achieved with these therapy regimens further questions the real economic advantage in using furazolidone, several eradication failure patients requiring a further therapy and a new test. In addition, no standardized rescue therapies have been proposed in those patients who failed the initial furazolidone-based treatment.

Our data failed to confirm the results of previous studies reporting a high efficacy with either a combination with bismuth salts or prolonged therapy,\[[@ref14]\] furazolidone dose being identified as the solely independent factor predicting eradication. However, the increased eradication rate achieved by using high-dose furazolidone is to some extent counterbalanced by the high prevalence of side effects. Of note, we computed that the incidence of severe side effects, that is, requiring therapy interruption, was as high as 12% of the overall patients complaining of side effects (4% of all treated cases), the rate being 6-fold higher in those patients receiving either high-dose furazolidone or a 14-day therapy. Such a finding could depend on the observation that furazolidone is a monoamine oxidase (MAO) inhibitor, and it may interact with foods or drugs in inducing side effects. The rate of both the overall and severe side effects appears higher than that observed following furazolidone-free therapies.\[[@ref68]\] The clinical relevance of side effects following furazolidone-based therapies is further highlighted by our observation that eradication rates at ITT were significantly lower than those achieved at PP analysis.

Although metronidazole is also listed as a potential carcinogen and it is "black boxed" by the FDA, it continued to be commercialized worldwide for humans. Due to the very high prevalence of primary metronidazole resistance in developing countries, furazolidone, for which bacterial resistance is generally low, was proposed for *H. pylori* therapy. Therefore, the performance \<80% of furazolidone-based treatments in developing areas was unexpected. Nevertheless, the resistance toward this antibiotic was highly variable, ranging from 1% to 25% in Iran,\[[@ref18][@ref69]\] and from 0% to 40% in China.\[[@ref70]\] Moreover, despite a cross-resistance between furazolidone and metronidazole not being reported, the cure rate with furazolidone-based therapies was significantly lower in metronidazole resistant than in susceptible strains.\[[@ref71]\] This finding further undermines the role of furazolidone-based regimens in developing countries with high imidazoles resistance rates.

In conclusion, furazolidone-based regimens achieved low eradication rates, despite antibiotic combinations and treatment duration. High-dose furazolidone increases the cure rate, but it significantly increases incidence of severe side effects. On this basis, our study suggests that the patients have to be clearly informed on the possible genotoxic and carcinogenetic effects for which furazolidone is not currently approved for animal use by the FDA and both human and animal use by EMA. We have to kill *H. pylori*, but primarily save the patients!
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